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ABSTRACT 1 
Purpose 2 
CHEK2*1100delC is a founder variant in European populations conferring a 2-3 fold increased risk of 3 
breast cancer (BC). Epidemiologic and family studies have suggested that the risk associated with 4 
CHEK2*1100delC is modified by other genetic factors in a multiplicative fashion. We have 5 
investigated this empirically using data from the Breast Cancer Association Consortium (BCAC).  6 
Methods 7 
With genotype data of 39,139 (624 1100delC carriers) BC patients and 40,063 (224) healthy controls 8 
from 32 BCAC studies, we analyzed the combined risk effects of CHEK2*1100delC and 77 common 9 
variants in terms of a polygenic risk score (PRS) and pairwise interaction.  10 
Results 11 
The PRS conferred an odds ratio (OR) of 1.59 [95% CI 1.21-2.09] per standard deviation for BC for 12 
CHEK2*1100delC carriers and 1.58 [1.55-1.62] for non-carriers. No evidence for deviation from the 13 
multiplicative model was found. The OR for the highest quintile of the PRS was 2.03 [0.86-4.78] and 14 
for the lowest quintile 0.52 [0.16-1.74] for CHEK2*1100delC carriers, corresponding to over 34.0% 15 
and less than 15.0% life-time risk, respectively.  16 
Conclusion 17 
Our results confirm the multiplicative nature of risk effects conferred by CHEK2*1100delC and the 18 
common susceptibility variants. Furthermore, the PRS could identify the carriers at a high life-time 19 
risk for clinical actions. 20 
Keywords: Breast cancer; CHEK2*1100delC; Polygenic risk score (PRS); common variants; Breast 21 
Cancer Association Consortium (BCAC) 22 
23 
13 
 
INTRODUCTION 1 
The protein truncating mutation CHEK2*1100delC (checkpoint kinase 2) is a moderate penetrance 2 
breast cancer risk variant with relative risk estimate of 2-3 fold.
1, 2
 However, several studies have 3 
shown that the absolute risk of breast cancer in CHEK2*1100delC carriers is markedly higher in 4 
women with a family history than without,
3-5
 and that CHEK2*1100delC carriers have a higher 5 
probability of developing bilateral breast cancer.
6
 These observations are quantitatively consistent 6 
with a simple polygenic model suggesting that CHEK2*1100delC combines multiplicatively with other 7 
genetic loci. However, this has not yet been established empirically.   8 
Genome wide association studies have identified common genetic variants that are associated with 9 
increased risk of breast cancer. A polygenic risk score (PRS), based on 77 low penetrance variants has 10 
been estimated to explain approximately 12-14% of the excess familial risk and shown to identify 11 
individuals at highest genetic risk at the population level.
7, 8
 Some of these variants predominantly 12 
predispose to either estrogen receptor positive (ER+) or estrogen receptor negative (ER-) disease, 13 
which represent the two main etiological subclasses of breast cancer.
9
 CHEK2*1100delC carriers are 14 
more strongly predisposed to ER+ disease: about 90% of carrier tumors are ER+ in comparison to 77-15 
78% of non-carrier tumours.
10
  16 
Here, we investigate the synergistic risk effects attributable to CHEK2*1100delC and the common 17 
breast cancer susceptibility variants both individually and summarized in terms of the PRS.
7, 8
  18 
PATIENTS AND METHODS 19 
Study participants 20 
Female invasive breast cancer patients and healthy controls of European ancestry were included 21 
from studies participating in the Breast Cancer Association Consortium (BCAC)(Table S1). Data from 22 
a study were included if the study provided genotype data of the common variants from at least one 23 
breast cancer patient carrying the 1100delC variant. This selection yielded data from 32 studies and 24 
14 
 
a total of 79 202 study subjects, including 848 CHEK2*1100delC carriers (Table S2) for pairwise 1 
interaction analyses.  Complete quality controlled
7, 10
 genotype data for all 77 common variants and 2 
CHEK2*1100delC were available from 33 624 study subjects (369 CHEK2*1100delC carriers, Table S2). 3 
This data were used in the analyses involving the PRS. 4 
All participating studies were approved by their institutional review committees. Each study 5 
followed national guidelines for participant inclusion and for informed consent procedures. 6 
Genotyping 7 
All variants except CHEK2*1100delC were genotyped centrally using a custom Illumina iSelect 8 
genotyping array (iCOGS, Illumina, Inc. San Diego, CA, USA) as part of the COGS consortium studies 9 
as described earlier.
7, 8
 CHEK2*1100delC was primarily genotyped using a custom made TaqMan 10 
assay (Applied Biosystems, Foster City, CA, USA), with a small minority being genotyped using 11 
iPLEX.
10
 In addition to the 38,549 study subjects genotyped using the iCOGS array, 40,653 BCAC 12 
study subjects were genotyped for up to 25 of the common risk variants and these data were used in 13 
the pairwise interaction analysis (Table S2, Table S3). These samples were genotyped by 14 
independent studies following BCAC genotyping standards as described previously.
11, 12
 15 
Statistical analyses 16 
Statistical analyses were performed using Stata SE 10 (StataCorp, Texas, USA) and R version 2.15.2.
13
 17 
For the common variants a log-additive model was assumed; i.e. the risk was analyzed in terms of 18 
the number of disease-associated alleles [0, 1, 2] carried. For practical reasons, CHEK2*1100delC was 19 
assumed to follow a dominant inheritance model (i.e. rare homozygotes (n=19) were combined with 20 
heterozygotes). All analyses were adjusted for study and seven principal components defined on the 21 
basis of the genome-wide data from the iCOGS project as described earlier.
7
 22 
Polygenic risk score 23 
15 
 
In order to investigate the combined effects of the 77 common variants and CHEK2*1100delC, a 1 
polygenic risk score (PRS) based on the main effects of the common variants was calculated using 2 
the formula: i
n
i
i ORa¦
 1
2log   3 
where n is the number of loci included in the model, a is the number of susceptibility alleles in locus i 4 
and OR is the per allele odds ratio for breast cancer, estimated separately for each variant in the 5 
whole data set (Table S4 ?ĐŽůƵŵŶ “ůů ? ? ?dŚĞWZ^ǁĂƐstandardized by mean and standard deviation 6 
of the PRS distribution among the healthy individuals.
8
 Noteworthy, of pairs of linked variants with 7 
r2>0.75, we included in the PRS only the lead variant (rs2981579, not rs2981582; rs12662670, not 8 
rs3757318; rs554219, not rs614367). Furthermore, we did not include in the analyses any imputed 9 
data, nor rs17879961, the CHEK2 missense variant I157T, because the number of study subjects 10 
carrying both 1100delC and I157T was very low (n=5).  The interaction between PRS and 11 
CHEK2*1100delC was assessed by comparing nested logistic regression models: a model including 12 
the PRS and 1100delC genotype and a model supplemented with an interaction term, coded as the 13 
product of the PRS and 1100delC. In analyses of the PRS and positive family history of breast cancer, 14 
positive family history was defined as at least one first degree relative with breast cancer. 15 
The cumulative life-time breast cancer risk of CHEK2*1100delC carriers in different PRS-percentiles 16 
was derived assuming an average life-time risk of 23%
14
 and previously published relative risk 17 
estimates associated with the PRS.
8
  18 
Pairwise interaction analyses 19 
We tested for pairwise interaction between each common variant and CHEK2*1100delC as 20 
described above for the interaction between the PRS and 1100delC. P-values were corrected for 77 21 
parallel tests using the Benjamini-Hochberg method.
15
 Furthermore, the OR for breast cancer was 22 
estimated separately for each of the common variants for the whole dataset and for the subgroup of 23 
1100delC carriers. These analyses were also performed separately on the subgroup of breast cancer 24 
16 
 
patients with ER+ disease, because 1100delC is associated with ER+ breast cancer.
10
 Statistical power 1 
was estimated as previously suggested for risk interaction analyses.
16
 2 
RESULTS 3 
We analyzed the combined effects of CHEK2*1100delC and 77 common low penetrance breast 4 
cancer risk variants using data from the international Breast Cancer Association Consortium (Table 5 
S2). The PRS summarizing the individual effects of the common variants was strongly associated with 6 
breast cancer risk among CHEK2*1100delC carriers (OR per unit standard deviation 1.59 [1.21 - 2.09], 7 
P=0.0008) and the OR was similar to that in non-carriers (1.58 [1.55 - 1.62], Pinteraction 0.93). ORs for 8 
the highest and lowest quintiles of the PRS distribution were 2.03 [0.86 - 4.78] and 0.52 [0.16 - 1.74] 9 
for CHEK2*1100delC carriers, respectively, when compared to the middle quintile (Table 1). Both 10 
estimates were well in line with those made among non-carriers.  11 
The OR associated with CHEK2*1100delC in the analysis data set 2.99 [2.32  ? 3.85] was attenuated, 12 
when the model was adjusted for positive family history of breast cancer. Also, the OR associated 13 
with the PRS was slightly attenuated (Table 2). Any significant interaction between risk effects 14 
associated with 1100delC, PRS and positive family history was not found. However, in a case-only 15 
analysis there was a significant association between the PRS and family history of breast cancer, 16 
among both CHEK2*1100delC carriers (OR 1.29 [1.01 - 1.65], P=0.04) and non-carriers (OR 1.17 [1.12 17 
- 1.21], P=4E-16) (Figure S1).  18 
When the common variants were considered individually, we found nominally significant 19 
interactions between five variants and CHEK2*1100delC for overall breast cancer (rs11249433, 20 
rs11780156, rs204247, rs2981582 and rs704010; Table S4a). Two of these represented synergistic 21 
(more than multiplicative) and three antagonistic interactions (the estimated effect in 1100delC 22 
carriers being in the opposite direction to that in non-carriers). However, none of the interactions 23 
were significant after correction for multiple testing. Nine variants showed a nominally significant 24 
interaction for ER-positive breast cancer (Table S4b).  25 
17 
 
DISCUSSION 1 
Our analyses on the synergistic effects of CHEK2*1100delC and 77 common low penetrance variants 2 
on breast cancer risk give strong support to the predicted multiplicative polygenic model.
8, 17, 18
 3 
While this has previously been shown for combinations of low penetrance variants,
8
 and for variants 4 
in combination with BRCA1 and BRCA2 mutations,
19
 this is the first direct demonstration for a 5 
 “ŵŽĚĞƌĂƚĞ ?ƌŝƐŬŐĞŶĞĂŶĚŚĂƐŝŵƉŽƌƚĂŶƚŝŵƉůŝĐĂƚŝŽŶƐĨŽƌƌŝƐŬƉƌĞĚŝĐƚŝŽŶ ? The PRS was a significant 6 
risk factor for CHEK2*1100delC carriers, and the estimated OR per unit standard deviation was very 7 
similar in CHEK2*1100delC carriers and in non-carriers, consistent with the hypothesis that the 8 
common susceptibility variants combine with the rare CHEK2*1100delC variant in an approximately 9 
multiplicative fashion. Similarly, the PRS risk estimates for the highest and lowest quintiles did not 10 
differ between the CHEK2*1100delC carriers and non-carriers. These two estimates made for the 11 
CHEK2*1100delC carriers alone did not reach statistical significance (Table 1), possibly reflecting 12 
limited statistical power due to the relatively low number of healthy variant carriers (Table S2). 13 
However, this is the largest cohort genotyped for CHEK2*1100delC and these common variants, and 14 
even though some of the point estimates are not significant as such, they are consistent with the 15 
previous reports. Most importantly, we did not find evidence for deviation from the multiplicative 16 
model, suggesting that the PRS could be used in risk stratification of 1100delC carriers as it can be 17 
used for non-carriers. 18 
The unadjusted OR for the CHEK2*110delC variants (Table 2) was higher in our analysis data set than 19 
in previous reports.
2, 14
 Adjusting for positive family history markedly attenuated the 20 
CHEK2*1100delC associated, suggestive of some oversampling of familial cases. The PRS was also 21 
slightly attenuated after the adjustment. However, CHEK2*1100delC, PRS and family history 22 
remained significant risk factors in the combined model (Table 2) suggesting that the common 23 
variants together explain part of the excess familial risk as previously suggested,
17
 but that the PRS 24 
has predictive value also in breast cancer families segregating CHEK2*1100delC. 25 
18 
 
Recently, a large study estimating the risk associated with CHEK2*1100delC in relation to age, tumor 1 
subtype and family history reported the cumulative life-time risk for 1100delC carriers to be about 2 
23%.
14
 Assuming that the genetic risk attributable to the common variants (the PRS) would vary 3 
around this estimate similarly as published previously for non-carriers (OR higher than 1.48 [1.39 - 4 
1.57] or lower than 0.65 [0.60  ? 0.70] for percentiles above 80% or lower than 20%, respectively),8 5 
20% of the 1100delC carriers with highest PRS would have life-time risk higher than 34.0% [32.0% - 6 
36.1%] exceeding the threshold for the high-risk category (>30%) according to the UK NICE 7 
guidelines for familial breast cancer.
20
 Similarly, for the 20% of 1100delC carriers with lowest PRS, 8 
the life-time risk would be lower than 15.0% [13.8% - 16.1%], i.e. close to population risk (<17%). 9 
These observations imply that, if CHEK2*1100delC is to be used in risk prediction, it can be made 10 
more effectively by including in the prediction also the PRS representing the risk modifying effects of 11 
the common variants. 12 
CHEK2*1100delC carrier cancers do not represent a phenotypically distinct subgroup of breast 13 
carcinomas. Instead, the phenotypic diversity of CHEK2*1100delC associated cancers resembles that 14 
of breast tumors in general.
10
 Thus, it was not surprising that the relative risks conferred by the 15 
common variants were similar for the CHEK2*1100delC carriers and for non-carriers, and no 16 
significant pairwise interaction was found. We estimated that we had sufficient statistical power 17 
(80%) to exclude the possibility of such pairwise interaction between CHEK2*1100delC and any of 18 
the common variants that would have an effect size of 2.5 (OR for interaction term higher than 2.5) 19 
but not enough power to investigate interactions comparable in magnitude to the risk effects 20 
associated with the low penetrance variants (OR 1.1-1.5). Thus, it remains possible that more 21 
modest departures from a multiplicative model may exist. If so, however, much larger case-control 22 
studies, perhaps combined with pedigree analyses, will be required to detect them. 23 
In conclusion, our analyses confirm the predicted multiplicative relationship between 24 
CHEK2*1100delC and the common low penetrance variants. Hence, the PRS could be similarly 25 
applied for risk prediction for the variant carriers as for the general population. Most importantly, 26 
19 
 
the PRS could help identifying the high risk group of the CHEK2*1100delC carriers, who would best 1 
benefit from clinical intervention. 2 
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